



Please cite the Published Version

Gavillet, H., Hatfield, Lauren , Hardman, M., Einarsson, G.G., Thornton, C.S., Parkins, M.D., Duckers, J., Bomberger, J.M., Hilliam, Y., Lee, S.E., Lord, R.W., Jones, A., Horsley, A., Daniels, T.W.V., Teneback, C.C., Wargo, M.J., Schutz, K., Rivett, Damian  and van der Gast, C. (2025) WS08.03Remodelling of cystic fibrosis respiratory microbiota in response to extended elextacaftor/tezacaftor/ivacaftor therapy. [Conference or Workshop Item]

DOI: <https://doi.org/10.1016/j.jcf.2025.03.536>

Publisher: Elsevier

Version: Accepted Version

Downloaded from: <https://e-space.mmu.ac.uk/640228/>

Usage rights:  [Creative Commons: Attribution 4.0](https://creativecommons.org/licenses/by/4.0/)

Additional Information: This is an accepted manuscript of a paper first presented at the 48th European Cystic Fibrosis Conference 2025.

Enquiries:

If you have questions about this document, contact openresearch@mmu.ac.uk. Please include the URL of the record in e-space. If you believe that your, or a third party's rights have been compromised through this document please see our Take Down policy (available from <https://www.mmu.ac.uk/library/using-the-library/policies-and-guidelines>)

Remodelling of cystic fibrosis respiratory microbiota in response to extended Elexacaftor–Tezacaftor–Ivacaftor therapy

H. Gavillet¹, L. Hatfield², M. Hardman³, G.G. Einarsson⁴, C.S. Thornton⁵, M.D. Parkins⁵, J. Duckers⁶, J.M. Bomberger⁷, Y. Hilliam⁷, S.E. Lee⁸, R.W. Lord⁹, A. Jones⁹, A. Horsley⁹, T.W.V. Daniels¹⁰, C.C. Teneback¹¹, M.J. Wargo¹², K. Schutz¹², D.W. Rivett², C. van der Gast^{1,13}

¹ Department of Applied Sciences, Northumbria University, Newcastle, UK

² Department of Life Sciences, Manchester Metropolitan University, Manchester, UK

³ Swansea University Medical School, Institute of Life Science, Swansea, United Kingdom

⁴ Queens University Belfast, School of Pharmacy, Belfast, United Kingdom

⁵ University of Calgary, Department of Medicine, Calgary, Canada

⁶ Cardiff and Vale University Health Board, All Wales Adult Cystic Fibrosis Centre, Cardiff, United Kingdom

⁷ Dartmouth College, Giesel School of Medicine, Hanover, United States

⁸ Brigham and Women's Hospital, Division of Otolaryngology, Boston, United States

⁹ Manchester University NHS Foundation Trust, Manchester Adult Cystic Fibrosis Centre, Manchester, United Kingdom

¹⁰ University Hospital Southampton NHS Trust, Wessex Adult Cystic Fibrosis Service, Southampton, United Kingdom

¹¹ Larner College of Medicine, Department of Medicine, Vermont, United States

¹² Larner College of Medicine, Department of Microbiology and Molecular Genetics, Vermont, United States

¹³ Northern Care Alliance NHS Foundation Trust, Department of Respiratory Medicine, Salford, United Kingdom

Background: The introduction of the highly effective CFTR modulator Elexacaftor/Tezacaftor/Ivacaftor (ETI) has revolutionised clinical outcomes for adults with CF (awCF) eligible for treatment. Despite this little is understood about the long-term impact of ETI on the respiratory microbiota in awCF.

Aims: In this multi-centre study, we investigated changes to the respiratory microbiota of awCF from before onset of ETI therapy to on-ETI therapy of up to 3 years.

Methods: Respiratory samples were collected from 303 awCF from 6 centres in the UK (Cardiff, Manchester, & Southampton), Canada (Calgary), and USA (Dartmouth & Vermont). This consisted of pre-ETI samples stratified to severe, moderate, and mild disease groups based on %FEV₁, and on-ETI samples taken at approximately 6 months, 1, 2, & 3 years. Samples from 11 non-CF healthy participants were included as a comparator group. Microbiota sequencing was performed on all samples.

Results: Microbiota diversity increased with therapy duration. With diversity at years 2 and 3 being comparable ($P>0.05$) to that observed in the mild disease pre-ETI and healthy groups. Microbiota composition became increasingly similar to mild CF/healthy groups with increasing therapy duration but was still significantly different ($P<0.05$) at 3 years. Dominance of CF pathogens reduced with therapy duration, with a shift to microbiota characterised by strict anaerobes associated with better clinical outcomes. Despite the reduction in abundance many CF pathogens still persisted.

Conclusions: Long-term ETI therapy resulted in positive changes in the respiratory microbiota, typically associated with better clinical outcomes and microbiota more closely resembling mild CF/healthy microbiota. Despite a positive trajectory towards a healthy-like microbiota, we posit that progression in awCF is impeded by the cumulative effects of progressive airway and lung parenchymal damage, along with the impacts of long-term and continued antibiotic therapy.